7,400 Shares in Bristol-Myers Squibb (NYSE:BMY) Purchased by Parvin Asset Management LLC

Parvin Asset Management LLC acquired a new stake in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 7,400 shares of the biopharmaceutical company's stock, valued at approximately $419,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in BMY. Wealthspire Advisors LLC increased its position in shares of Bristol-Myers Squibb by 0.6% in the fourth quarter. Wealthspire Advisors LLC now owns 28,679 shares of the biopharmaceutical company's stock worth $1,622,000 after purchasing an additional 170 shares during the last quarter. Edmp Inc. grew its stake in Bristol-Myers Squibb by 0.4% in the 4th quarter. Edmp Inc. now owns 41,599 shares of the biopharmaceutical company's stock worth $2,353,000 after buying an additional 171 shares in the last quarter. Trust Point Inc. increased its holdings in shares of Bristol-Myers Squibb by 1.9% in the 4th quarter. Trust Point Inc. now owns 9,423 shares of the biopharmaceutical company's stock worth $533,000 after buying an additional 172 shares during the last quarter. Bedel Financial Consulting Inc. raised its position in shares of Bristol-Myers Squibb by 3.2% during the 4th quarter. Bedel Financial Consulting Inc. now owns 5,690 shares of the biopharmaceutical company's stock valued at $340,000 after buying an additional 175 shares in the last quarter. Finally, Horst & Graben Wealth Management LLC lifted its holdings in shares of Bristol-Myers Squibb by 2.4% during the 4th quarter. Horst & Graben Wealth Management LLC now owns 7,538 shares of the biopharmaceutical company's stock worth $426,000 after acquiring an additional 179 shares during the last quarter. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Bristol-Myers Squibb Trading Up 1.9 %

Shares of BMY stock traded up $0.95 during trading hours on Friday, reaching $50.56. The company's stock had a trading volume of 14,165,790 shares, compared to its average volume of 12,966,960. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $63.33. The stock has a market capitalization of $102.89 billion, a P/E ratio of -11.44, a P/E/G ratio of 2.07 and a beta of 0.41. The firm's fifty day simple moving average is $55.68 and its 200 day simple moving average is $56.37.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.50 by $0.30. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The business had revenue of $11.20 billion for the quarter, compared to analysts' expectations of $10.77 billion. During the same quarter in the previous year, the business posted ($4.40) earnings per share. The firm's revenue for the quarter was down 5.6% compared to the same quarter last year. Equities research analysts expect that Bristol-Myers Squibb will post 6.74 EPS for the current year.

Bristol-Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, May 1st. Investors of record on Friday, April 4th were paid a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a yield of 4.91%. The ex-dividend date was Friday, April 4th. Bristol-Myers Squibb's payout ratio is currently 92.88%.

Wall Street Analysts Forecast Growth

BMY has been the topic of a number of research reports. Truist Financial raised their price target on Bristol-Myers Squibb from $62.00 to $65.00 and gave the company a "buy" rating in a research report on Wednesday, January 8th. William Blair reissued a "market perform" rating on shares of Bristol-Myers Squibb in a report on Friday, April 25th. UBS Group cut their target price on Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a research note on Friday, April 11th. Cantor Fitzgerald restated a "neutral" rating and issued a $55.00 price objective on shares of Bristol-Myers Squibb in a report on Tuesday, April 22nd. Finally, Jefferies Financial Group cut their price objective on shares of Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating for the company in a research note on Wednesday, April 23rd. Two equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have issued a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Bristol-Myers Squibb has an average rating of "Hold" and a consensus target price of $58.00.

Insider Buying and Selling at Bristol-Myers Squibb

In other news, EVP Samit Hirawat bought 4,250 shares of the firm's stock in a transaction dated Friday, April 25th. The stock was purchased at an average price of $47.58 per share, with a total value of $202,215.00. Following the transaction, the executive vice president now owns 83,513 shares of the company's stock, valued at approximately $3,973,548.54. The trade was a 5.36 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.09% of the company's stock.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.